RecruitingPhase 4NCT06195228

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Sponsor

Fudan University

Enrollment

800 participants

Start Date

Jan 1, 2020

Study Type

INTERVENTIONAL

Conditions

Advanced Thyroid Cancer Patients Who Received Target Therapy

Summary

This is a retrospective and prospective real-world clinical study of molecular typing in the treatment of advanced thyroid cancer. The retrospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 participated hospitals from January 2020 to December 2023 were retrieved. The number of previous treatment lines was not limited. Patients who met the inclusion criteria were screened according to the inclusion and exclusion criteria. Demographic information, clinical characteristics, tumor treatment history, medication regimen, adverse reactions, molecular test results, survival follow-up results and other data were collected. The prospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 Chinese hospitals from January 2024 to April 2027 were enrolled.

Eligibility

Plain Language Summary

Simplified for easier understanding

This study collects real-world data on people with advanced thyroid cancer to understand how genetic testing (molecular typing) influences treatment decisions and outcomes. **You may be eligible if...** - You have been diagnosed with locally advanced, recurrent, or metastatic thyroid cancer that cannot be fully removed by surgery - Your cancer type includes radioiodine-resistant differentiated thyroid cancer, medullary thyroid cancer, poorly differentiated thyroid cancer, or anaplastic thyroid cancer - You have had genetic testing on your tumor before enrolling - You have signed informed consent **You may NOT be eligible if...** - You are currently enrolled in another drug clinical trial - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGdabrafenib plus trametinib with or without PD-1 antibody

advanced thyroid cancer patients who harbor BRAF V600E mutation

DRUGentrectinib or larotrectinib with or without anti-PD-1 antibdoy

advanced thyroid cancer patients who harbor NTRK mutation

DRUGpralsetinib or selpercatinib with or without anti-PD-1 antibdoy

advanced thyroid cancer patients who harbor RET fusion or medullary thyroid carcinoma patients who habor RET mutation.

DRUGanlotinib or anlotinib plus anti-PD-1 antibody

For patients with medullary carcinoma, if there is no RET gene mutation or RET gene mutation is unknown

DRUGlenvatinib plus anti-PD-1 antibody

Advanced thyroid cancer patients who don't harbor the above gene mutation or could not afford the cost of precision treatment even with the above gene mutation

DRUGOther Targets: precise treatment based on the target

Advanced thyroid cancer patients who had other treatment targets not included above

Locations(8)

Fujian Cancer Hospital

Fuzhou, Fujian, China

Henan Cancer Hospital

Zhengzhou, Henan, China

Union Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, Hubei, China

Caixia Liu

Hohhot, Inner Mongolia, China

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Shanxi Cancer Hospital

Shanxi, Taiyuan, China

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

Peking union medical college hospital

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06195228